e-ISSN:2319-9865
p-ISSN:2322-0104

Research & Reviews: Journal of Medical and Health Sciences

The Genetics of Alzheimer's: A Review

Khadijah B*

Amity Institute of Biotechnology, Noida, India

Review Article

Received date: 23/08/2016
Accepted date: 07/09/2016
Published date: 14/09/2016

***For Correspondence**

Khadijah B, Amity Institute of biotechnology, Noida, India, Tel: +919891986960.

E-mail: khadijah234@gmail.com

Keywords: Dementia, Degenerative Disorders, Aging, Depression, Early onset Alzheimer's, Late onset Alzheimer's, GWAS, APOE

ABSTRACT

Alzheimer's is a kind of neurological disorder that interferes with memory, behaviour and thinking ability of people. It is the most common form of dementia which progresses slowly and becomes worse overtime. One of the most common risk factor is aging and most of the people with Alzheimer's are 65 and older. Be that as it may, Alzheimer's is not only an ailment of seniority. Up to 5 per cent of individuals with the ailment have early onset Alzheimer's (otherwise called more youthful onset), which frequently shows up when somebody is in their 40s or 50s. 486,000 deaths were caused in 2010 due to Alzheimer's. In 2015, there were approximately 48 million people worldwide who were affected with this disease. In developed countries, Alzheimer's is considered as one of the most financially costly diseases.

INTRODUCTION

In 1906: Alzheimer's disease was first described by Dr. Alois Alzheimer in his patient named as Auguste D who experienced loss of memory, fearful feelings, and changes in psychology. Dr. Alzheimer viewed in the autopsy that there was shrinkage in and around nerve cells in her brain [1-15].

Alzheimer's is an interminable neurodegenerative issue that for the most part begins gradually and deteriorates after some time [5,6]. Transient memory misfortune or trouble in recollecting late occasions is one of the early manifestations of Alzheimer's. As the illness advances gradually, side effects like issues with dialect, confusion, mind-set swings, loss of inspiration, trouble in self-care, and certain behavioural changes happens [16,17]. As the condition compounds persistent regularly pull back from their family and society. All the while substantial capacities are lost, eventually prompting passing. The normal future after finding is three to nine years [18-25].

The reason for Alzheimer's illness is ineffectively caught on. Around 70% of the danger is accepted to be hereditary with loads of qualities required, for instance Apo lipoprotein E [7,10]. Other danger components incorporate a past filled with head wounds, dejection or hypertension. Despite a concentration gradient favouring diffusion from brain to plasma the brain maintains high levels of ascorbic acid (AA) [26-30].

It is clear that the immune system has an important role in the progression of this disease although it is considered to be a neurodegenerative disorder. New immunotherapies using humoral and cell based approaches are currently under investigation for the treatment and prevention of Alzheimer's disease.

GENETICS BEHIND ALZHEIMER'S

Development of amyloid plaques and neurofibrillary occurs and there is loss of connections between nerve cells (neurons) in the brain and the death of these nerve cells results in the development of this disease. Alzheimer's are of two types: Early onset and late onset [31].

Early-Onset Alzheimer's Disease

e-ISSN:2319-9865
p-ISSN:2322-0104

Early-onset Alzheimer's disease occurs in people with age group of 30 to 60. FAD is known to be caused by inherited changes in one of the three genes resulting in a type.

A tyke whose natural mother or father conveys transformed quality for early-onset FAD has a 50/50 shot of acquiring that change. On the off chance that the tyke acquires the transformation then he has a high risk of growing early onset Alzheimer's [32-36].

Early-onset FAD is caused by different single-gene mutations on chromosomes 1,14 and 21, which results in the formation of abnormal proteins which in turn results in the generation of harmful form of amyloid plaques which is the hallmark of this disease. Formation of abnormal amyloid precursor protein (APP) occurs due to mutation in chromosome 21, a mutation on chromosome 14 causes the formation of abnormal presenilin 1 and a mutation on chromosome 1 leads to abnormal presenilin 2 [35,37-42].

Dominantly Inherited Alzheimer Network (DIAN), an international partnership to study families with early-onset FAD is helping scientists all over the world to continuously research on the cause behind early onset of this disease [43-52]. By analysing the Alzheimer's-related changes in brain scientists hope to find how and why the disease develops in both its early- and late-onset forms.

Late-Onset Alzheimer's disease

In this form of the disease symptoms begin to appear in mid 60s or later [16,53-59]. The prime reasons for late-onset Alzheimer's are not yet known, but rather are thought to incorporate a blend of hereditary, ecological, and way of life elements that influence a man's danger for building up the sickness [60-73]. According to the researchers a specific gene is responsible for the occurrence of this disease. A mutated form of the apolipoprotein E (APOE) gene on chromosome 19 can result in development of this disease [45,48,74]. APOE comes in several different forms, or alleles:

- APOE ε2 is rare and is known to provide some protection against this disease. People with this allele usually develop this disease later in their life unlike APOE ε4.
- APOE ε3, the most common allele, is thought to play a neutral role in the development of the disease, i.e., neither decreases or increases the risk of the disease [75-81].
- APOE ε4 allele expands the danger for Alzheimer's ailment and is likewise connected with an early onset of the sickness. A man having more APOE ε4 alleles builds the danger of creating Alzheimer's. APOE ε4 is referred to as danger variable quality as it expands a man's danger of building up the malady. Acquiring an APOE ε4 allele does not generally imply that a man will create Alzheimer's. A few people with an APOE ε4 allele never get the sickness, and other people who don't have an APOE ε4 build up the illness.

DIAGNOSIS

Genome-wide association study (GWAS), also known as whole genome association study (WGA study, or WGAS), is used as a tool for the diagnosis of the disease at genetic level. GWASs typically focus on associations between single-nucleotide polymorphisms (SNPs) and traits like major diseases [82-91]. Different regions in the genome of the organism have been identified by the researchers which are known to cause Alzheimer's or increase its risk [92-95].

A technique called entire genome sequencing decides the complete DNA grouping of a man's genome at a solitary time. Another technique called entire exome sequencing takes a gander at the parts of the genome that specifically code for the proteins. Utilizing these two methodologies, specialists can recognize new qualities that add to or ensure against malady hazard [46,96-100]. Late disclosures have prompted new experiences about natural pathways required in Alzheimer's and may one day lead to viable intercessions.

CONCLUSION

There is as of now no cure for Alzheimer's ailment, however there is a great deal that should be possible to empower somebody to live well with the condition. This will include drug and non-drug consideration, backing and exercises.

The individual ought to have an opportunity to converse with an expert about their analysis. This could be a specialist or psychological wellness nurture, a clinical clinician, word related advisor or GP. Data on the backing that is accessible and where to go for further exhortation is crucial in helping somebody to stay physically and rationally well. Experts, for example, the GP and staff at the memory administration or neighbourhood Alzheimer's Society can prompt on what may best address the issues of the individual and of those tending to them.

There are medication medicines for Alzheimer's infection that can briefly mitigate a few side effects or back off their movement in a few people. (The names in sections are regular brands of these medications.)

A man in the gentle or direct phases of Alzheimer's illness or blended dementia will regularly be recommended a medication, for example, donepezil (e.g. Aricept), rivastigmine (e.g. Exelon) or galantamine (e.g. Reminyl). The medication may help with

memory issues, enhance fixation and inspiration, and help with parts of day by day living, for example, cooking, shopping or leisure activities. A man in the moderate or extreme phases of Alzheimer's illness or blended dementia might be offered an alternate sort of medication: memantine (e.g. Ebixa). This may help with mental capacities and day by day living, and simplicity upsetting or testing practices, for example, disturbance and hallucinations. For more data see factsheet 407, Drug medicines for Alzheimer's infection.

In the event that somebody is discouraged or restless, talking treatments, (for example, intellectual behavioural treatment) or medication medicines, (for example, antidepressants) may likewise be attempted. Directing may help the individual change in accordance with the conclusion.

There are numerous approaches to help somebody stay autonomous and adapt to memory misfortune. These incorporate handy things like building up a routine or utilizing a week by week pill box. There are other assistive innovation items accessible, for example, electronic updates and timetable timekeepers. For more data see factsheet 526, coping with memory misfortune.

It is helpful for a man with all Alzheimer's up with exercises that they appreciate. Numerous individuals advantage from practicing their psyche with perusing or riddles. There is confirmation that going to sessions to keep rationally dynamic helps (subjective incitement). Biography work, in which somebody shares their backgrounds and makes an individual record, may help with memory, mind-set and prosperity. As the dementia exacerbates, numerous individuals appreciate more broad memory exercises.

After some time, changes in the individual's conduct, for example, unsettling or animosity turn out to be more probable. These practices are frequently a sign that the individual is in trouble. This could be from a medicinal condition, for example, torment; since they misjudged something or somebody; or maybe in light of the fact that they are baffled or under-empowered. Individualized methodologies ought to search for, and attempt to address, the hidden cause. General non-drug approaches frequently additionally offer assistance. These incorporate social collaboration, music, memory, exercise or different exercises that are important for the individual. They are for the most part attempted before extra medications are considered, especially antipsychotics.

REFERENCES

1. Caldeira GL, et al. Impaired transcription in Alzheimer’s disease: Key role in mitochondrial dysfunction and Oxidative Stress. J Alzheimers Dis. 2013;34:115-131.
2. Fleming JL, et al. The role for oxidative stress in aberrant DNA methylation in Alzheimer’s disease. Curr Alzheimer Res. 2012;9:1077-1096.
3. Venkateshappa C, et al. Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: implications for neurodegeneration in Alzheimer’s disease. Neurochem Res. 2012;37:1601-1614.
4. Mohsenzadegan M and Mirshafiey A. The immunopathogenic role of reactive oxygen species in alzheimer disease. Iran j allergy asthma immunol. 2012;203-216.
5. Kim K, et al. A comparison of three types of trail making test in the Korean elderly: higher completion rate of trail making test-black and white for mild cognitive impairment. J Alzheimers Dis Parkinsonism. 2016;6:239.
6. Wu Y, et al. Observation study of the retina with the Alzheimer ’s disease or amnestic mild cognitive impairment patients. J Clin Exp Ophthalmol. 2016;7:545.
7. Zhou B, et al. Shanghai cohort study on mild cognitive impairment: study design and baseline characteristics. J Alzheimers Dis Parkinsonism. 2016;6:224.
8. Shinno H, et al. Alterations in rapid eye movement sleep parameters predict for subsequent progression from mild cognitive impairment to Alzheimer’s disease. J Alzheimers Dis Parkinsonism. 2016;6:218.
9. Nakaya M. Cognitive impairment in Bipolar disorder: comparison with cognitive impairment in Schizophrenia. Bipolar Disord. 2016;2:106.
10. Rima R. A Cohort study of cognitive impairment in patients of Multiple Sclerosis. J Mult Scler. 2015;2:161.
11. Cintra MTG,et al. P300 evoked potential and risk of mild cognitive impairment progression to Alzheimer’s Dementia: A Literature Review. J Neurol Neurophysiol. 2015;6:322.
12. Nicole S, et al. Safety modality for X-linked severe combined Immunodeficiency gene therapy. J Cell Sci Ther. 2012;3:121.
13. Samir AF. Anti- Metastatic gene therapy in patients with advanced epithelial ovarian cancer (EOC). J Cell Sci Ther. 2013;S15-001.

14. Ann P, et al. Corneal gene therapy in veterinary medicine: A review. J Veterinar Sci Technol. 2013;S8-001.

15. David MM and Roland WH. Liver-directed adeno-associated viral gene therapy for hemophilia. J Genet Syndr Gene Ther. 2013;S1-009.

16. Takayoshi W, et al. Double β-alanine substitutions incorporated in 12-ring Pyrrole-Imidazole Polyamides for lengthened DNA minor groove recognition. Adv Tech Biol Med. 2016;4:175.

17. Esteban OP. Novel findings in familial non-medullary thyroid cancer genetics. Thyroid Disorders Ther. 2015;4:e119.

18. Rao AA, et al. Computational analysis of mutations in colon cancer genes reveals a possible role of micro satellite in mutagenesis. J Proteomics Bioinform. 2008.

19. Wang X. An exploration of mutation status of cancer genes in breast cancers. Next Generat Sequenc & Applic. 2014;1:103.

20. Ponizovskiy MR. Biophysical and biochemical transmutation of mitochondrial function in cancer genesis. Biochem Anal Biochem. 2013;2:137.

21. Breast cancer genetic testing awareness, attitudes and intentions of Latinas living along the US-Mexico border: A qualitative study. J Community Med Health Edu. 2012;2:152.

22. Bonucci M. Integrated cancer therapy: Treat the person to cure the cancer. Interdiscip J Microinflammation. 2016.

23. Lay FD and Liang G. Rethinking demethylating agents in epigenetic cancer therapy. J Mol Pharm Org Process Res. 2016;4:133.

24. Khalid A and Javaid MA. Matrix metalloproteinases: New targets in cancer therapy. J cancer sci therol. 2016;8:146.

25. Hussen RSD and Heidelberg T. Drug carriers in cancer therapy: administration, formulation and characterization. IJPR. 2016.

26. Dong J, et al. Targeting ROS for cancer therapy. Chemotherapy (Los Angel). 2016;5:199.

27. Vaze OS. Pharmaceutical nanocarriers (liposomes and micelles) in cancer therapy. J Nanomed Nanotechnol. 2016;7:e138.

28. Varol M. Ultrasound-mediated cancer therapy as a non-invasive and repeatable treatment strategy. J App Pharm. 2016;8:2.

29. Efferth T and Shan L. Natural products for cancer therapy "is economic success reachable? Med Aromat Plants. 2016;5:E174.

30. Rosaria CM. Addressing the potential role of fingolimod in cancer therapy. Med Chem (Los Angeles). 2016;6:195.

31. Fernández A. Anticancer therapy based on suppression of pathways recruited to cope with metabolic stress. Metabolomics. 2016;6:e144.

32. Her SC and Her C. Targeting DNA double-strand break repair in cancer therapy. J Mol Genet Med. 2015;9:E106.

33. Stephenson D, et al. Alzheimer's and Parkinson's diseases face common challenges in therapeutic development: role of the precompetitive consortium, coalition against major diseases. J Alzheimers Dis Parkinsonism. 2015;5:183.

34. Utkin YN, et al. What animal models of parkinsonism tell us about the distinct nicotinic acetylcholine receptors involved in pathogenesis? J Alzheimers Dis Parkinsonism. 2015;5:181.

35. Calderón-Garcidueñas L, et al. The intestinal barrier in air pollution-associated neural involvement in Mexico City residents: Mind the gut, the evolution of a changing paradigm relevant to Parkinson disease risk. J Alzheimers Dis Parkinsonism. 2015;5:179.

36. Devasena T and Francis AA.P. Nanotoxicity-induced Alzheimer disease and Parkinsonism: Not further than diagnosis. J Alzheimers Dis Parkinsonism. 2015;5:178.

37. Yamamoto T, et al. Assessment of a new magnetic device to monitor swallowing in Parkinson's disease. J Neurol Neurophysiol. 2015;6:267.

38. Santiago JA, et al. Understanding the role diet plays in Parkinson's disease could lead to better disease management. Clin Exp Pharmacol. 2015;5:e135.

39. Werner FM and Covenas R. Might Combined GABAA agonists and NMDA antagonists have a therapeutic and maybe a prophylactic effect in Alzheimer's and Parkinson's disease? J Cytol Histol. 2015;6:298.

40. Olalekan O and Sanya OJ. NMDA R/VDR in fish melanocytes; receptor targeted therapeutic model and mechanism in Parkinson's disease. J Biomol Res Ther. 2014;3:114.

41. Arkun K, et al. Effect of lewy bodies on mitochondrial DNA copy numbers and deletion burden in Parkinson's disease

substantia nigra Neurons. J Alzheimers Dis Parkinsonism. 2015;5:175.

42. Tortolero GS, et al. EEG findings in diffuse lewy body disease and Parkinson's disease with dementia. Brain Disord Ther. 2015;4:156.
43. Wang XH, et al. Impact of deep brain stimulation therapy on autonomic disturbances and related symptoms of Parkinson's disease. Brain Disord Ther. 2015;4:150.
44. Stephens SJ, et al. Fluoxetine-induced atypical serotonin syndrome with hallucinations masquerading as a Parkinsonian syndrome. Fam Med Med Sci Res. 2014;3:147.
45. Mohammed NB, et al. Single dose does matter! an interesting case of Parkinsons hyperpyrexia syndrome. J Neurol Disord. 2014;2:191.
46. Oguro H, et al. Randomized trial of repetitive transcranial magnetic stimulation for apathy and depression in Parkinson's disease. J Neurol Neurophysiol. 2014;5:242.
47. Ono S. FMT-PET for the early diagnosis of Parkinson's disease . J Neurol Disord. 2014;2:i104.
48. McDonald KR, et al. Personality style in behavioural disturbances in Parkinson's disease. J Neurol Neurophysiol. 2014;5:251.
49. Haram A, et al. Clinical correlates of RBD in early Parkinson disease. J Alzheimers Dis Parkinsonism. 2014;4:174.
50. Okada Y, et al. Rehabilitation for postural deformities in Parkinson's disease: An update and novel findings. J Nov Physiother. 2014;4:233.
51. Okada Y, et al. In-home posture evaluation and visual feedback training to improve posture with a kinect- based system in Parkinson's disease. J Nov Physiother. 2014;4:232.
52. Vanessa KH, et al. Forced exercise for freezing of gait in post STN DBS Parkinson's disease patients. J Alzheimers Dis Parkinsonism. 2014;4:171.
53. Whitesman P. Preliminary set theory-type analysis of proteins associated with Parkinson's disease. J Alzheimers Dis Parkinsonism. 2014;4:170.
54. Bitner A, et al. The role of multidrug interactions in the safety of pharmacotherapy for concomitant Parkinson's disease and arterial hypertension in Poland. J Pharmacovigilance. 2014;2:151.
55. Barboza NM, et al. The effect of an exercise-based intervention to the quality of life of patients suffering from Parkinson's disease: Prospective study. J Yoga PhysTher. 2014;4:170.
56. Turner TH, et al. Epidermal growth factor (EGF) is associated with memory and executive functioning in progressed Parkinson's disease. J Alzheimers Dis Parkinsonism. 2014;4:164.
57. Hanby MF, et al. Emotional and cognitive processing deficits in people with Parkinson's disease and apathy. J Alzheimers Dis Parkinsonism. 2014;4:156.
58. Camargo CHF, et al. Orthostatic hypotension and its relationship to the clinical course of patients with Parkinson's disease. J Alzheimers Dis Parkinsonism. 2014;4:155.
59. Seitz RJ, et al. Monitoring of visuomotor coordination in healthy subjects and patients with stroke and Parkinson's disease: An application study using the PABLOR-device. Int J Neurorehabilitation. 2014;1:113.
60. Bryan Lieber BA, et al. Motion sensors to assess and monitor medical and surgical management of Parkinson's disease. Int J Phys Med Rehabil. 2014;2:221.
61. Leroi I, et al. Apathy and emotional blunting in Parkinson's disease. Brain Disord Ther. 2014;3:141.
62. Lu J. Modeling Parkinson's disease with human induced pluripotent stem cells. Clon Transgen. 2014;3:e113.
63. Werner FM and Covenas R. Classical neurotransmitters and neuropeptides involved in Parkinson's disease: A multi-neurotransmitter system. J Cytol Histol. 2014;5:266.
64. Byl N, et al. Aerobic exercise enabled with rehabilitation technology improves mobility and balance of patients with Parkinson's disease: A quality assurance report. Int J Phys Med Rehabil. 2014;2:220.
65. Lieberman A. Falls in Parkinson disease: The relevance of short steps. J Nov Physiother. 2014;4:209.
66. Sadek HL, et al. The inflammatory cytokines in the pathogenesis of Parkinson's disease. J Alzheimers Dis Parkinsonism. 2014;4:148.
67. Suvorit SB, et al. Postencephalitic Parkinsonism in a patient with mumps infection: A case report. J Neuroinfect Dis. 2014;5:162.

68. Joanna C. Rehabilitation procedures aimed at decreasing motor symptoms in Parkinson's disease. Int J Phys Med Rehabil. 2014;S5:009.

69. Wheeler CJ, et al. T-lymphocyte deficiency exacerbates behavioral deficits in the 6-OHDA unilateral lesion rat model for Parkinson's disease. J Neurol Neurophysiol. 2014;5:209.

70. Mao CJ, et al. Prominent non-motor symptoms in patients with Parkinson's disease and pain. J Neurol Neurophysiol. 2014;5:208.

71. Mally J. Non-invasive brain stimulation and its supposed site of action in the rehabilitation of Parkinson's disease and stroke. Int J Neurorehabilitation. 2014;1:e103.

72. Miyazaki Y, et al. MIBG myocardial scintigraphy can predict the occurrence of wearing-off phenomenon in early-stage Parkinson's disease. J Neurol Disord. 2014;2:154.

73. Mehanna R. Cognitive changes after deep brain stimulation in Parkinson's disease: A critical review. Brain Disord Ther. 2014;3:116.

74. Blanchet PG and Hoffman PR. Factors influencing the effects of delayed auditory feedback on dysarthric speech associated with Parkinson 's disease. Commun Disord Deaf Stud Hearing Aids. 2014;2:106.

75. Amran S, et al. the Pharmacokinetic study of aspirin, paracetamol and naproxen with magnesium sulfate. Pharm Anal Acta. 2015;6:372.

76. Maheswari PD, et al. Micellar solubilization in the formulation development of poorly soluble naproxen. Pharmaceut Reg Affairs. 2013;2:108.

77. Rothman KJ and Lanza LL Estimated risks of fatal events associated with acetaminophen, Ibuprofen and naproxen sodium used for analgesia. Adv Pharmacoepidem Drug Safety. 2013;2:124.

78. Silva Solon LG, et al. Comparative bioavailability of a generic and two compounded naproxen sodium suspensions administered to rats. J Bioanal Biomed. 2010;2:048-054.

79. Setiawati E, et al. Bioequivalence study with two naproxen sodium tablet formulations in healthy subjects. J Bioequiv Availab. 2009;1:028-033.

80. Reddy YR, et al. Rapid simultaneous determination of sumatriptan succinate and naproxen sodium in combined tablets by validated ultra-performance liquid chromatographic method. J Anal Bioanal Tech. 2011;2:121.

81. Abid MR and Sellke FW. Antioxidant therapy: Is it your gateway to improved cardiovascular health? Pharm Anal Acta. 2015;6:323.

82. Robles L, et al. Role of oxidative stress in the pathogenesis of pancreatitis: Effect of antioxidant therapy. Pancreatic Dis Ther. 2013;3:112.

83. Azu OO. The male genital tract in the era of highly active antiretroviral therapy (HAART): Implication for antioxidant therapy. J AIDS Clinic Res. 2012;3:169.

84. Dawood M and Efferth T. Medicinal plants and DNA methylation of cancer. Med Aromat Plants. 2015;4:e161.

85. Teschler S, et al. Aberrant DNA methylation of ribosomal RNA genes in human cancer. Mol Biol. 2015;4:128.

86. Wang Y, et al. Altered expression and DNA methylation profiles of ercc6 gene in lens tissue from age-related cortical cataract. J Clin Exp Ophthalmol. 2015;6:392

87. Su J, et al. Advances in bioinformatics tools for high-throughput sequencing data of DNA methylation. Hereditary Genet. 2012;1:107.

88. Szilagyi K, et al. Exploring DNA methylation of MYLK as a contributor to acute respiratory distress syndrome disparities. J Pulm Respir Med.2013;3:e127.

89. Liu J, et al. Liquid chromatography tandem mass spectrometry for the measurement of global DNA methylation and hydroxymethylation. J Proteomics Bioinform. 2013;S2:005.

90. Leo E and Martinelli G. DNA methylation in chronic myeloid leukemia. J Mol Genet Med. 2014;08:118.

91. Gigek CO, et al. SIRT1, IGFBP-3 and CAV1 Promoter DNA methylation in aging. Transl Med (Sunnyvale). 2014;4:133.

92. Patten DA, et al. Reactive oxygen species: Stuck in the middle of neurodegeneration. J Alzheimers Dis. 2010;2:S357-367.

93. Smith MA, et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA. 1997;94:9866–9868.

94. Leibson CL, et al. risk of Dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol 1997.

95. Sinha BK. Roles of free radicals in the toxicity of environmental pollutants and toxicants. J Clinic Toxicol. 2013;S13:e001.

96. Butnariu M and Samfira I. Free radicals and oxidative stress. J Bioequiv Availab. 2012;4: iv-vi.

97. Butnariu M. Action and protection mechanisms of free radicals. J Pharmacogenomics Pharmacoproteomics. 2012;3:e129.

98. Niknam M, et al. Anti- inflammatory effects of dietary antioxidants in patients with coronary artery disease. Endocrinol Metab Syndr. 2015;4:207.

99. Garcia-Sierra F. Commentary on ubiquitin is associated with early truncation of tau protein at aspartic acid 421 during the maturation of neurofibrillary tangles in Alzheimer disease. J Med Surg Pathol. 2016;1:121.

100. Paris D, et al. Anatabine attenuates tau phosphorylation and oligomerization in P301S tau transgenic mice. Brain Disord Ther. 2014;3:126.